JP2018500546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500546A5 JP2018500546A5 JP2017525337A JP2017525337A JP2018500546A5 JP 2018500546 A5 JP2018500546 A5 JP 2018500546A5 JP 2017525337 A JP2017525337 A JP 2017525337A JP 2017525337 A JP2017525337 A JP 2017525337A JP 2018500546 A5 JP2018500546 A5 JP 2018500546A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- scopolamine
- benzalkonium chloride
- rodent
- candidate agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 45
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 25
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 25
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 25
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 25
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 25
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 25
- 229960002646 scopolamine Drugs 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 241000283984 Rodentia Species 0.000 claims description 23
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- 206010013774 Dry eye Diseases 0.000 claims description 8
- 206010015946 Eye irritation Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 231100000013 eye irritation Toxicity 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 210000004969 inflammatory cell Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086263P | 2014-12-02 | 2014-12-02 | |
| US62/086,263 | 2014-12-02 | ||
| PCT/US2015/063084 WO2016089807A1 (en) | 2014-12-02 | 2015-12-01 | Animal model for dry eye and methods of use of such animals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500546A JP2018500546A (ja) | 2018-01-11 |
| JP2018500546A5 true JP2018500546A5 (enExample) | 2018-12-27 |
| JP6692808B2 JP6692808B2 (ja) | 2020-05-13 |
Family
ID=55024246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525337A Expired - Fee Related JP6692808B2 (ja) | 2014-12-02 | 2015-12-01 | ドライアイ用動物モデルおよびこうした動物の使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170360013A1 (enExample) |
| EP (1) | EP3226853B1 (enExample) |
| JP (1) | JP6692808B2 (enExample) |
| KR (1) | KR20170100483A (enExample) |
| CN (1) | CN107106553A (enExample) |
| AU (1) | AU2015355169A1 (enExample) |
| CA (1) | CA2967432A1 (enExample) |
| ES (1) | ES2759729T3 (enExample) |
| IL (1) | IL252077A0 (enExample) |
| MX (1) | MX2017007295A (enExample) |
| RU (1) | RU2706787C2 (enExample) |
| SG (1) | SG11201703572SA (enExample) |
| WO (1) | WO2016089807A1 (enExample) |
| ZA (1) | ZA201703052B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2909998T3 (es) * | 2016-10-14 | 2022-05-11 | I Com Medical Gmbh | Método para establecer, restablecer y preservar la homeostasis de la superficie ocular |
| US12303527B2 (en) | 2018-04-18 | 2025-05-20 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| KR102429281B1 (ko) * | 2020-05-25 | 2022-08-05 | (주)노바셀테크놀로지 | 신규 안구건조증 치료용 약학적 조성물 |
| CN113519461A (zh) * | 2021-07-06 | 2021-10-22 | 江西中洪博元生物技术有限公司 | 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用 |
| WO2023215261A1 (en) * | 2022-05-02 | 2023-11-09 | Ocular Services On Demand, Llc | Mammalian eye models |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2384679A1 (en) * | 1999-09-08 | 2001-03-15 | Srinivasan Venkateshwaran | Using quaternary ammonium salts for transdermal drug delivery |
| EP2598131A1 (fr) * | 2010-07-29 | 2013-06-05 | Laboratoires Fournier S.A. | Composes pour le traitement/la prevention des maladies inflammatoires oculaires |
-
2015
- 2015-12-01 SG SG11201703572SA patent/SG11201703572SA/en unknown
- 2015-12-01 ES ES15816590T patent/ES2759729T3/es active Active
- 2015-12-01 CN CN201580065760.3A patent/CN107106553A/zh active Pending
- 2015-12-01 MX MX2017007295A patent/MX2017007295A/es unknown
- 2015-12-01 CA CA2967432A patent/CA2967432A1/en not_active Abandoned
- 2015-12-01 EP EP15816590.2A patent/EP3226853B1/en active Active
- 2015-12-01 KR KR1020177012469A patent/KR20170100483A/ko not_active Withdrawn
- 2015-12-01 US US15/532,527 patent/US20170360013A1/en not_active Abandoned
- 2015-12-01 RU RU2017118978A patent/RU2706787C2/ru not_active IP Right Cessation
- 2015-12-01 JP JP2017525337A patent/JP6692808B2/ja not_active Expired - Fee Related
- 2015-12-01 AU AU2015355169A patent/AU2015355169A1/en not_active Abandoned
- 2015-12-01 WO PCT/US2015/063084 patent/WO2016089807A1/en not_active Ceased
-
2017
- 2017-05-03 IL IL252077A patent/IL252077A0/en unknown
- 2017-05-03 ZA ZA2017/03052A patent/ZA201703052B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Song et al. | Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina | |
| AU2017274197B2 (en) | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| JP2012046483A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| JP2010536797A5 (enExample) | ||
| JP2016520573A5 (enExample) | ||
| JP2017537089A5 (enExample) | ||
| RU2017118978A (ru) | Модель сухого кератоконъюнктивита на животных и способы применения таких животных | |
| PH12016501357A1 (en) | Pharmaceutical preparation containing pyridylamino acetic acid compound | |
| Goyagi et al. | Dexmedetomidine improves the histological and neurological outcomes 48 h after transient spinal ischemia in rats | |
| JP2015007136A5 (enExample) | ||
| US20220339127A1 (en) | Druggable target to treat retinal degeneration | |
| IL277088B1 (en) | Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury | |
| JP2020531511A5 (enExample) | ||
| JP2017519799A5 (enExample) | ||
| AU2017261303A1 (en) | Ophthalmic compositions | |
| MX379191B (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| Al Zamil | Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema | |
| WO2017139336A1 (en) | Method of preventing and treating retinal microvasculature inflammation using c-met signaling pathway inhibition | |
| FI3519050T3 (fi) | Koostumuksia silmätautien hoitamiseksi | |
| NZ622403A (en) | Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method | |
| RU2014126070A (ru) | Способы лечения и предотвращения глазных заболеваний | |
| CN120078761A (zh) | α-酮戊二酸在制备高血压促血管新生药物中的应用 | |
| JP2018523648A5 (enExample) |